{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:45:28Z","timestamp":1794264328713,"version":"4.9.0"},"reference-count":27,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fogarty International Center of the National Institutes of Health","award":["D43TW011976."],"award-info":[{"award-number":["D43TW011976."]}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144708"],"award-info":[{"award-number":["R01HL144708"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Expanding treatment for hypertension requires ensuring access to affordable, high-quality blood pressure (BP) lowering medications. We describe the design, implementation and evaluation of a BP-lowering medication drug revolving fund (DRF) embedded in the Hypertension Treatment in Nigeria (HTN) Programme in 60 primary healthcare centres (PHCs) in the Federal Capital Territory, Nigeria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the exploration, preparation, implementation and sustainment framework to describe the DRF design and implementation and the reach, effectiveness, adoption, implementation and maintenance framework to report implementation outcomes. From June 2022 to December 2023, the DRF programme was implemented, and the data were collected from PHCs\u2019 drug stock and finance records, quarterly DRF-supportive supervision visits and the HTN Programme. We performed descriptive statistics using complete case analysis and used an interrupted time-series design to explore temporal trends in the 3-month rolling average rate of BP-lowering prescriptions dispensed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DRF design and implementation strategies included stakeholder engagement, leveraging the existing supply systems, developing medication and financial management protocols, training of site staff and DRF-supportive supervision visits, including joint problem solving. DRF was implemented in all 60 PHCs (100% reach). Adoption was high, with an increase in facilities selling DRF-supported medications from 80% to 100% (p value=0.01). Fidelity improved, including correct financial documentation (70%\u2013100%; p value&lt;0.0001) and stock cards (68%\u201394%; p value=0.0004). Effectiveness was high with low rates of medication stockouts of DRF-supported medications (1.7%\u201316%), with most medications at affordable prices, but a 12.1% drop in BP-lowering medications dispensing rate when the DRF replaced study-supplied free medication. Maintenance was high, with 100% of PHCs having a functional DRF after 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A DRF programme to expand access to BP-lowering medications was implemented and effective in the Federal Capital Territory, Nigeria, and may serve as a model for other hypertension control programmes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-018029","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:50:26Z","timestamp":1763628626000},"page":"e018029","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Design and implementation of a drug revolving fund for hypertension treatment in primary care setting of the Federal Capital Territory, Nigeria"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04158154","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04158154","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9277-3208","authenticated-orcid":false,"given":"Grace Julcit","family":"Shedul","sequence":"first","affiliation":[{"name":"Pharmacy, University of Abuja Teaching Hospital, Gwagwalada, Nigeria"},{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia N","family":"Ugwuneji","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-9653","authenticated-orcid":false,"given":"Erica L","family":"Jamro","sequence":"additional","affiliation":[{"name":"Cardiovascular Division and Global Health Center, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Banigbe","sequence":"additional","affiliation":[{"name":"Resolve to Saves Lives, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ponzing","sequence":"additional","affiliation":[{"name":"Pharmacy, University of Abuja Teaching Hospital, Gwagwalada, Nigeria"},{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inuwa","family":"Okpe","sequence":"additional","affiliation":[{"name":"Pharmacy, University of Abuja Teaching Hospital, Gwagwalada, Nigeria"},{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna R","family":"Ripiye","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"},{"name":"Family Medicine, University of Abuja Teaching Hospital, Gwagwalada, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikechukwu A","family":"Orji","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-908X","authenticated-orcid":false,"given":"Gabriel Lamkur","family":"Shedul","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"},{"name":"Family Medicine, University of Abuja Teaching Hospital, Gwagwalada, Nigeria"},{"name":"Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Osagie","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-0554","authenticated-orcid":false,"given":"Abigail S","family":"Baldridge","sequence":"additional","affiliation":[{"name":"Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois, USA"},{"name":"Havey Institute of Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namratha R","family":"Kandula","sequence":"additional","affiliation":[{"name":"Havey Institute of Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okeoma","family":"Erojikwe","sequence":"additional","affiliation":[{"name":"Resolve to Saves Lives, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Huffman","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia"},{"name":"School of Public Health, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dike","family":"Ojji","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria"},{"name":"Department of Internal Medicine, Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-7437","authenticated-orcid":false,"given":"Lisa R","family":"Hirschhorn","sequence":"additional","affiliation":[{"name":"Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Havey Institute of Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2025112000500509000_10.11.e018029.1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S413546"},{"key":"2025112000500509000_10.11.e018029.2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/jch.14220","article-title":"Prevalence, awareness, treatment, and control of hypertension in Nigeria in 1995 and 2020: A systematic analysis of current evidence","volume":"23","author":"Adeloye","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025112000500509000_10.11.e018029.3","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2019.1670014","article-title":"Noncommunicable diseases, access to essential medicines and universal health coverage","volume":"12","author":"Beran","year":"2019","journal-title":"Glob Health Action"},{"key":"2025112000500509000_10.11.e018029.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063433","article-title":"Stakeholder perspectives on the demand and supply factors driving substandard and falsified blood pressure lowering medications in Nigeria: a qualitative study","volume":"12","author":"Shedul","year":"2022","journal-title":"BMJ Open"},{"key":"2025112000500509000_10.11.e018029.5","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.048561"},{"key":"2025112000500509000_10.11.e018029.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-003116","article-title":"Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya","volume":"5","author":"Tran","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2025112000500509000_10.11.e018029.7","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-015-0033-7","article-title":"Assessment of a revolving drug fund for essential asthma medicines in Benin","volume":"8","author":"Agodokpessi","year":"2015","journal-title":"J Pharm Policy Pract"},{"key":"2025112000500509000_10.11.e018029.8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/ijpp.12254","article-title":"The Revolving Fund Pharmacy Model: backing up the Ministry of Health supply chain in western Kenya","volume":"24","author":"Manji","year":"2016","journal-title":"Int J Pharm Pract"},{"key":"2025112000500509000_10.11.e018029.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/JAMPS\/2016\/25950","article-title":"Essential Drugs Revolving Fund Scheme in Nigeria; from the Edge of a Precipice towards Sustainability","volume":"8","author":"Ogbonna","year":"2016","journal-title":"JAMPS"},{"key":"2025112000500509000_10.11.e018029.10","first-page":"20","article-title":"An Evaluation of the Drug Revolving Fund (DRF) scheme in Nigeria: two decades after its adoption","volume":"1","author":"Ohaju-Obodo","year":"2006","journal-title":"Archives of Clinical Research"},{"key":"2025112000500509000_10.11.e018029.11","doi-asserted-by":"crossref","unstructured":"Maliyogbinda J . Commodity security: the role of drug revolving fund scheme in low- and middle-income countries. 2024.","DOI":"10.5772\/intechopen.112790"},{"key":"2025112000500509000_10.11.e018029.12","doi-asserted-by":"crossref","DOI":"10.1186\/s43058-022-00328-9","article-title":"Hypertension Treatment in Nigeria (HTN) Program: rationale and design for a type 2 hybrid, effectiveness, and implementation interrupted time series trial","volume":"3","author":"Baldridge","year":"2022","journal-title":"Implement Sci Commun"},{"key":"2025112000500509000_10.11.e018029.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-018-0842-6","article-title":"Systematic review of the Exploration, Preparation, Implementation, Sustainment (EPIS) framework","volume":"14","author":"Moullin","year":"2019","journal-title":"Implement Sci"},{"key":"2025112000500509000_10.11.e018029.14","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.89.9.1322"},{"key":"2025112000500509000_10.11.e018029.15","unstructured":"National bureau of statistics (Nigeria). Trading economics. (November 3, 2023). Monthly minimum wage in Nigeria from 2018 to 2023 (in 1,000 Nigerian Naira) [graph]. In statista. 2023."},{"key":"2025112000500509000_10.11.e018029.16","doi-asserted-by":"crossref","DOI":"10.1186\/s43058-021-00197-8","article-title":"Stakeholder perspectives to inform adaptation of a hypertension treatment program in primary healthcare centers in the Federal Capital Territory, Nigeria: a qualitative study","volume":"2","author":"Okoli","year":"2021","journal-title":"Implement Sci Commun"},{"key":"2025112000500509000_10.11.e018029.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-06320-8","article-title":"Capacity and site readiness for hypertension control program implementation in the Federal Capital Territory of Nigeria: a cross-sectional study","volume":"21","author":"Orji","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2025112000500509000_10.11.e018029.18","first-page":"6640133","article-title":"Affordability of Essential Medicines and Associated Factors in Public Health Facilities of Jimma Zone, Southwest Ethiopia","volume":"2021","author":"Mathewos Oridanigo","year":"2021","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"2025112000500509000_10.11.e018029.19","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.4102\/phcfm.v6i1.604","article-title":"Price, availability and affordability of medicines","volume":"6","author":"Mhlanga","year":"2014","journal-title":"Afr J Prim Health Care Fam Med"},{"key":"2025112000500509000_10.11.e018029.20","unstructured":"World Health Organization . WHO global surveillance and monitoring system for substandard and falsified medical products. Geneva, 2017."},{"key":"2025112000500509000_10.11.e018029.21","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.15236.1","article-title":"Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania","volume":"4","author":"Pisani","year":"2019","journal-title":"Wellcome Open Res"},{"key":"2025112000500509000_10.11.e018029.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-103121","article-title":"Implementation of a large-scale hypertension program in primary health centres in the Federal Capital Territory, Nigeria: an explanatory, sequential mixed-methods study","volume":"15","author":"Obiezu-Umeh","year":"2025","journal-title":"BMJ Open"},{"key":"2025112000500509000_10.11.e018029.23","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.26719\/2007.13.6.1476","article-title":"Achieving sustainability, quality and access: lessons from the world\u2019s largest revolving drug fund in Khartoum","volume":"13","author":"Witter","year":"2007","journal-title":"East Mediterr Health J"},{"key":"2025112000500509000_10.11.e018029.24","doi-asserted-by":"crossref","DOI":"10.1186\/s41256-024-00368-9","article-title":"Improving hypertension control in Nigeria: early policy implications from the Hypertension Treatment in Nigeria program","volume":"9","author":"Ogungbe","year":"2024","journal-title":"Glob Health Res Policy"},{"key":"2025112000500509000_10.11.e018029.25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/apa.14662","article-title":"Using the RE-AIM framework to evaluate the implementation of integrated community case management in Kenya","volume":"107 Suppl 471","author":"Onono","year":"2018","journal-title":"Acta Paediatr"},{"key":"2025112000500509000_10.11.e018029.26","unstructured":"Okojie J . Naira scarcity frustrates nigerians, worsens cost of living. Business Day; 2023. Available: https:\/\/businessday.ng\/news\/article\/naira-scarcity-frustrates-nigerians-worsens-cost-of-living\/"},{"key":"2025112000500509000_10.11.e018029.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.08.043"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-018029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:50:32Z","timestamp":1763628632000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-018029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjgh-2024-018029"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-018029","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}